Safe Analgesic Alternatives in Patients with NSAID-Exacerbated Respiratory Disease: The Role of Tramadol and Celecoxib
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Objective This study aimed to determine which analgesic agents can be safely administered to patients with nonsteroidal anti-inflammatory drug–exacerbated respiratory disease (N-ERD) and to evaluate the safety of tramadol as a potential alternative. Materials and Methods A total of 51 patients (34 females, 17 males; mean age, 39.5 ± 14.2 years) with a history of NSAID hypersensitivity were retrospectively analyzed. All patients underwent oral drug provocation tests with celecoxib, paracetamol, nimesulide, meloxicam, and tramadol. In patients with a history of hypersensitivity to a single NSAID, negative skin test results were followed by an oral aspirin challenge to confirm N-ERD. Statistical analyses were performed using chi-square, Mann–Whitney U, and Spearman correlation tests, with p < 0.05 considered statistically significant. Results Eleven patients (21.6%) had hypersensitivity to a single NSAID; all demonstrated negative skin test results but positive aspirin challenge outcomes, indicating non–IgE-mediated mechanisms. Celecoxib and tramadol showed significantly lower reaction rates compared with nimesulide, paracetamol, and meloxicam (p < 0.001). More than half of the cohort (52.9%) required moderate- or high-dose inhaled corticosteroids, while 25.5% of patients with severe asthma were receiving biologic therapy. Conclusion Celecoxib and tramadol were well tolerated in all patients with N-ERD, suggesting that these agents are safe and effective analgesic alternatives. Individualized evaluation and supervised provocation testing remain essential to ensure safety before clinical use.
Fields of Study & Subjects
Drug-Induced Adverse Reactions
Asthma and respiratory diseases
Inflammatory mediators and NSAID effects
Publication details
- Journal / source
- Annals of Medical Research
- Publication date
- 1 January 2026
- Language
- EN